Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC).
R. Borson
No relevant relationships to disclose
W. G. Harker
No relevant relationships to disclose
J. E. Reeves
No relevant relationships to disclose
D. Drosick
No relevant relationships to disclose
J. T. Beck
Research Funding - Bristol-Myers Squibb; Genentech; Lilly
S. J. Hager
No relevant relationships to disclose
W. L. Horvath
No relevant relationships to disclose
J. Bromund
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
H. Zeigler
No relevant relationships to disclose
D. Tai
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
D. A. Yardley
No relevant relationships to disclose